RUNX1 and hematopoietic and lymphoid cell neoplasm: Analysis of the Project Score Cancer Dependency Map (Sanger Institute) (Behan et al. 2019) and the Avana CRISPR screen data set (DepMap, Broad Institute) (Doench et al. 2016; Meyers et al. 2017) showed that MYC is pan-essential, ELF1 is essential in one cancer cell line, RUNX1 is essential in multiple hematopoietic cancer cells in the DepMap data set, and MAZ and ELF1 were not reported to be essential in any hematopoietic cancer models (Supplemental Fig. S5A,B).